Association of non-selective β blockers with the mortality risk in decompensation cirrhosis: a systematic review and meta-analysis
Frontiers in Pharmacology · 05.08.2026 · 17
DOI: 10.3389/fphar.2026.1920788 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 05.08.2026. Verfasst von Junchao Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Aims The role of non-selective beta-blockers (NSBBs) in patients with decompensated cirrhosis remains controversial, with conflicting evidence regarding their safety and efficacy across different stages of disease severity. This meta-analysis aimed to evaluate the association between NSBB use and mortality in patients with decompensated cirrhosis.
Methods
We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science from inception to May 2026. Studies reporting the risk of mortality associated with NSBB use in decompensated cirrhosis were included. Pooled HRs with 95% confidence intervals (CIs) were calculated using random-effects models. Subgroup analyses were performed based on mean arterial pressure (MAP), Model for End-stage Liver Disease (MELD) score, NSBB dosage, and cirrhosis complications.
Results
24 studies comprising 120,072 patients were included. NSBB use was associated with a significant 25% reduction in mortality risk (HR = 0.75, 95%CI: 0.66–0.85, P < 0.01), albeit with substantial heterogeneity (I 2 = 87%). The protective effect was consistent across studies employing propensity score matching (HR = 0.72, 95%CI: 0.59–0.88, P < 0.01) and multivariable regression analyses (HR = 0.74, 95%CI: 0.61–0.89, P < 0.01) by sensitivity analysis. Subgroup analyses revealed that the mortality benefit was more pronounced in patients with consistent baseline blood pressure (BP) between groups (HR = 0.82, 95%CI: 0.89–0.97), MELD score ≤15 (HR = 0.72, 95%CI: 0.56–0.92), and those receiving low-dose NSBBs (HR = 0.74, 95%CI:0.60–0.91). Conversely, NSBB use was not associated with reduced mortality in patients with inconsistent baseline BP (HR = 1.25, 95%CI: 0.52–3.00), MELD score >15 (HR = 0.92, 95%CI: 0.63–1.35), or high-dose NSBB therapy (HR = 0.92, 95%CI: 0.64–1.32). The presence of ascites, spontaneous bacterial peritonitis or hepatic encephalopathy appeared to not aggravate the survival risk.
Conclusion
Decompensated cirrhosis should not be regarded as an absolute contraindication to NSBB therapy; rather, the decision to initiate treatment, particularly at a low dose, may be guided by MAP and MELD scores. Nonetheless, these findings require further validation through randomized controlled trials. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO , CRD420261406986.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China.
- Department of Gastroenterology, Xiamen Hospital Dongzhimen Hospital, Beijing University of Chinese Medicine, Xiamen, China.
- Department of Gastroenterology, Xiamen TCM Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Xiamen, China.
- Department of Infection, the First Affiliated Hospital of Xiamen University, Xiamen, China.
Zitieren
APA
Zhang, J., Lin, Y., & Weng, X. (2026). Association of non-selective β blockers with the mortality risk in decompensation cirrhosis: a systematic review and meta-analysis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1920788
Vancouver
Zhang J, Lin Y, Weng X. Association of non-selective β blockers with the mortality risk in decompensation cirrhosis: a systematic review and meta-analysis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1920788
BibTeX
@article{Zhang2026,
author = {Zhang, Junchao and Lin, Yehong and Weng, Xiaxia},
title = {Association of non-selective β blockers with the mortality risk in decompensation cirrhosis: a systematic review and meta-analysis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1920788}
}
EUVIMED